Production (Stage)
Dianthus Therapeutics, Inc.
DNTH
$18.31
-$0.98-5.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -12.29% | -38.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.29% | -38.95% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -12.29% | -38.95% | |||
| SG&A Expenses | 7.44% | 4.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.30% | 3.65% | |||
| Operating Income | -3.95% | -6.74% | |||
| Income Before Tax | -3.77% | -12.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.77% | -12.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.77% | -12.97% | |||
| EBIT | -3.95% | -6.74% | |||
| EBITDA | -3.95% | -6.74% | |||
| EPS Basic | -1.56% | -10.40% | |||
| Normalized Basic EPS | -8.70% | -8.45% | |||
| EPS Diluted | -1.56% | -10.40% | |||
| Normalized Diluted EPS | -8.70% | -8.45% | |||
| Average Basic Shares Outstanding | 2.16% | 2.33% | |||
| Average Diluted Shares Outstanding | 2.16% | 2.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||